Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 8

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---

ENDRA Life Sciences Inc. (“ENDRA”
or the “Company”) is designing a medical device for accurate liver fat measurement for use in metabolic disease detection
and management and GLP-1 drug eligibility and management in circumstances where other technologies are unavailable or impractical.

In 2025, the Company adopted a digital asset treasury
(“DAT”) strategy under which the principal holding in its treasury reserve on its balance sheet will be allocated to cryptocurrency,
and specifically a strategy of holding one to five decentralized finance digital assets. Additionally, the Company intends to monitor
ongoing developments in the regulatory environment around cryptocurrencies, including pending federal legislation, and may modify or expand
its DAT strategy to the extent it determines compliant with federal rules and regulations and not giving rise to a requirement that the
Company register as an investment company under the Investment Company Act of 1940, as amended (the “1940 Act”).      

ENDRA was incorporated on July 18, 2007 as a Delaware
corporation.

Note 2 - Summary of Significant Accounting
Policies

Use of Estimates

The preparation of the financial statements in
conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements
and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Management makes estimates that affect certain
accounts including inventory reserve, deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for
any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are
determined.

Principles of Consolidation

The Company’s consolidated financial statements
include all accounts of the Company and its consolidated subsidiaries and/or entities as of reporting period ending date(s) and for the
reporting period(s) then ended. All inter-company balances and transactions have been eliminated.

Basis of Presentation

The accompanying unaudited condensed consolidated
financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared
in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. In the opinion of
management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
Operating results for the nine months ended September